
- /
- Supported exchanges
- / US
- / AQST.NASDAQ
Aquestive Therapeutics Inc (AQST NASDAQ) stock market data APIs
Aquestive Therapeutics Inc Financial Data Overview
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder; and Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures. The company's proprietary pipeline of complex molecule products includes AQST-108, which is in phase 2, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, which is in phase 3, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Aquestive Therapeutics Inc data using free add-ons & libraries
Get Aquestive Therapeutics Inc Fundamental Data
Aquestive Therapeutics Inc Fundamental data includes:
- Net Revenue: 57 561 K
- EBITDA: -30 030 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-03
- EPS/Forecast: -0.1325
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Aquestive Therapeutics Inc News

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Initiated Anaphylm™ (epinephrine) Sublingual Film NDA filing process with FDAAnaphylm pre-commercial activities underway; launch expected in Q1 2026, if approved by the FDAInitial Anaphylm pediatric...


Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting
Data show Anaphylm maintains consistent stability and potency under extreme temperature and real-world conditions, including heat, freezing, and water submersionNew findings demonstrate dosing of Anap...

Coming FDA Approvals Could Send These 3 Drug Stocks Soaring
In the biotech and pharmaceutical world, FDA approval is the number one needle mover for drug stocks. Why? Because FDA approval for a drug or treatment can bring years or even decades of steady, high-...

Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
Aquestive Therapeutics, Inc. Appoints Abigail “Abbey” Jenkins, a veteran biotech executive with over 20 years of experience in commercial leadership, to Board of Directors WARREN, N.J., April 01...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.